GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (FRA:C17) » Definitions » Net Policyholder Benefits/Claims

Corvus Pharmaceuticals (FRA:C17) Net Policyholder Benefits/Claims


View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Corvus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).